Trademarks for Pharmaceuticals in Nepal (DDA + DoI)

Pharmaceutical trademarks in Nepal require dual clearance: registration with the Department of Industry (DoI) under the Patent, Design and Trade Mark Act 1965, plus drug-name approval from the Drug Administration Authority (DDA). A mark passing only one authority cannot legally appear on medicines sold within the country.

Key Takeaways

• Pharma brands face mandatory dual clearance involving both DoI trademark registration and separate DDA drug-name approval.
• Class 5 is the primary NICE classification for pharmaceuticals, ranking fourth overall in Nepal’s historical filing data.
• The DoI examines marks for distinctiveness and conflicts, while the DDA reviews names specifically for public safety and confusion risks.
• Trademark registration lasts seven years and is renewable indefinitely, distinct from separate DDA product licence cycles.
• Nepal operates on a first-to-file basis where unregistered use alone provides no statutory protection against later registrants.
• Foreign applicants must file directly through a local agent and may claim priority under the Paris Convention.

What makes pharmaceutical trademarks different in Nepal?

Pharmaceutical marks must satisfy two distinct regulators with different mandates. The Department of Industry examines whether a mark is distinctive and avoids conflict with earlier registered trademarks under general IP law. The Drug Administration Authority separately evaluates proposed drug names for public health risks, including confusing similarity to existing approved medicines or International Nonproprietary Name stems. Holding a valid DoI certificate does not guarantee DDA approval, making dual compliance essential for legal market entry.

Which NICE class covers medicines and supplements?

Class 5 is the primary classification for pharmaceuticals, medical preparations, veterinary substances, dietary supplements, and disinfectants. According to IP Sewa’s bulletin dataset covering over 70,000 entries, Class 5 ranks as the fourth most-filed category in Nepal with 4,620 recorded marks. Companies selling medicated cosmetics may also need Class 3, while pharmacy retail services fall under Class 35. Since Nepal requires separate applications per class, multi-category businesses must budget for multiple filings and examinations.

How do you register a pharmaceutical trademark in Nepal?

The registration path follows standard trademark procedures but requires parallel DDA engagement for full market authorization. Most pharmaceutical companies follow this sequence to align intellectual property protection with regulatory licensing timelines efficiently.

1. Search the DoI trademark database. Conduct a comprehensive search for identical or confusingly similar marks in Class 5 before investing in branding. Use the trademark conflict checker to identify potential barriers early.
2. Identify correct NICE classes. Confirm Class 5 coverage and map additional classes needed for retail or R&D activities using the NICE class finder.
3. File application with DoI. Submit Schedule 1(c) form with four specimens, notarised Power of Attorney, board resolution, and label. Foreign applicants must include certified home registration copies.
4. Examination and publication. The DoI examines for distinctiveness and conflicts under the Act. Qualified marks are published in the Industrial Property Bulletin for public notice.
5. Survive opposition window. Third parties may oppose within 90 days of publication. Unopposed or successfully defended marks proceed to registration upon fee payment.
6. Apply for DDA drug-name approval. Submit the proposed brand name alongside product dossier, INN, GMP certificate, and manufacturer licence to the Drug Administration Authority.
7. Receive dual clearance. Obtain both the DoI registration certificate and DDA product licence before marketing the medicine under that brand name in Nepal.

What documents does the DDA require for drug names?

The DDA approves drug names as part of product licensing rather than registering trademarks. Typical submissions include the proposed brand name, International Nonproprietary Name, formulation details, manufacturer’s licence, GMP certificate, and often a no-objection letter from foreign brand owners. The DDA cross-checks proposed names against approved drug databases to prevent dispensing errors caused by look-alike or sound-alike similarities. This public-health inquiry is entirely separate from DoI trademark examination, meaning a name clearing IP hurdles can still face rejection on safety grounds.

How long does dual clearance take?

DoI trademark registration typically takes 12 to 14 months from filing to certificate when unopposed, with six to eight months representing a favourable best case. DDA product licensing runs on a separate track dependent on dossier completeness and review queues. Experienced applicants initiate DDA preparation during DoI examination to overlap timelines where possible. Budget approximately 12 to 18 months total before a new branded medicine achieves full dual clearance for legal market launch in Nepal.

What legal principles govern pharma trademark disputes?

Nepalese courts have established critical enforcement principles relevant to pharmaceutical brands. In Madan Prasad Lamsal v. Repsona Publications Pvt. Ltd. (NKP 2068, Decision No. 8686), the Supreme Court confirmed that only registered marks receive statutory protection; unregistered use alone creates no enforceable rights. For deceptive similarity, Kansai Nerolac Paints Ltd. v. Rukmani Chemical Industries Pvt. Ltd. (NKP 2077, Decision No. 10561) established that minor prefixes or suffixes do not distinguish copied marks, and bad-faith registrations face no time-bar for cancellation. Foreign pharmaceutical companies should note Sun Fitting Pvt. Ltd. v. Sandeep Industries (NKP 2076, Decision No. 10304), which affirmed Paris Convention protections for marks registered in their country of origin.

Common mistakes pharma companies make

Hypothetical example: Launching a paracetamol brand

Imagine a Nepali company launching paracetamol tablets under the brand "Fevril." The company first searches DoI records for conflicting Class 5 marks and finds none. It files a trademark application while simultaneously preparing its DDA dossier with formulation details, INN "Paracetamol," and GMP certificates. Once DoI issues the registration certificate after the opposition period, the company submits complete documentation to DDA. The authority confirms "Fevril" does not resemble existing approved drug names and grants the product licence. Had the company skipped DoI filing, another party could register "Fevril" later and force costly rebranding despite DDA approval.

Foreign pharmaceutical company requirements

Nepal operates outside the Madrid System, requiring foreign applicants to file directly through registered local agents. Required documents include notarised Power of Attorney, certified English copies of home-country registration certificates, and standard application forms. Paris Convention priority claims are available for home filings made within six months. Local distributors or manufacturer representatives must separately obtain DDA drug-name approval and product licences. Professional guidance helps navigate documentary requirements and coordinate dual-track timelines effectively through our contact page.

Renewal and maintenance obligations

Trademark registrations last seven years from the registration date and are renewable indefinitely for successive seven-year terms under the Act. Renewal applications must be filed within 35 days of expiry, with a six-month grace period available upon penalty payment. Failure to renew results in automatic cancellation, which jeopardizes any DDA product licence referencing that mark. Pharmaceutical companies should synchronize DoI renewal tracking with DDA licence renewal schedules to prevent coverage gaps that could disrupt market access or invite third-party squatting on abandoned marks.

In short

Pharmaceutical trademark protection in Nepal demands dual clearance through DoI registration and DDA drug-name approval. Neither gate is optional, and success requires coordinated IP strategy aligned with regulatory licensing. Early searching, proper class selection, and understanding enforcement precedents help avoid expensive missteps when bringing medicines to market.

People also search for

• How to register a trademark in Nepal
• How to choose the right trademark class in Nepal
• Documents required for trademark registration in Nepal
• How foreign companies register a trademark in Nepal
• What counts as a confusingly similar trademark in Nepal

Ready to secure your pharmaceutical brand? Start with a thorough database search using our trademark search service, then consult our team about dual-clearance strategy or begin your trademark registration filing today.